Tereza Škodová

Tereza Škodová

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jana VitkuJana Vitku
Jana Vitku
AVAnežka Varausová
Anežka Varausová
TŠTereza Škodová
Tereza Škodová
LKLucie Kolatorova
Lucie Kolatorova
MVMichala Vosatkova
Michala Vosatkova
MSMichaela Svojtkova
Michaela Svojtkova
Polycystic ovary syndrome (PCOS) and idiopathic hirsutism (IH) are androgen excess disorders requiring the determination of classic androgen levels for diagnosis. 11-oxygenated androgens have high androgenic potential, yet their clinical value in those disorders is not clear. Additionally, the role of endocrine disruptors (EDs), particularly in IH, remains understudied. We analyzed 25 steroids and 18 EDs in plasma samples from women with IH, PCOS, and controls using LC-MS/MS. Cytokine levels and metabolic parameters were assessed. Comparisons included non-obese women with PCOS (n = 10), women with IH (n = 12) and controls (n = 20), and non-obese versus obese women with PCOS (n = 9). Higher levels of 11-oxygenated androgens were observed in women with PCOS compared to those with IH, but not controls. Conversely, 11-oxygenated androgen levels were lower in women with IH compared to controls. Cytokine levels did not differ between women with IH and controls. Bisphenol A (BPA) levels were higher in obese women with PCOS compared to non-obese women with PCOS. Bisphenol S occurrence was higher in women with PCOS (90%) compared to controls (65%) and IH (50%). Significant correlations were found between androgens (11-ketotestosterone, androstenedione, testosterone) and insulin and HOMA-IR, as well as between immunomodulatory 7-oxygenated metabolites of DHEA and nine interleukins. Our data confirms that PCOS is a multiendocrine gland disorder. Higher BPA levels in obese women might exacerbate metabolic abnormalities. IH was not confirmed as an inflammatory state, and no differences in BPA levels suggest BPA does not play a role in IH pathogenesis.

31 October 2020 in Life
Verified
Journal Article
Open access
PDF file
GAGabriela Angelová
Gabriela Angelová
TŠTereza Škodová
Tereza Škodová
TPTerezie Prokopiusova
Terezie Prokopiusova
MMMagdalena Markova
Magdalena Markova
NHNatalia Hruskova
Natalia Hruskova
Kamila RasovaKamila Rasova
Kamila Rasova
Background: Only few studies have monitored the potential of physical activity training and physical therapy to modulate the reaction of the endocrine system. In this study, the effect of neuroproprioceptive facilitation and inhibition physical therapy on clinical outcomes and neuroactive steroids production in people with multiple sclerosis was evaluated. Moreover, we were interested in the factors that influence the treatment effect. Methods: In total, 44 patients with multiple sclerosis were randomly divided into two groups. Each group underwent a different kind of two months ambulatory therapy (Motor program activating therapy and Vojta’s reflex locomotion). During the following two months, participants were asked to continue the autotherapy. Primary (serum level of cortisol, cortisone, 7α-OH-DHEA, 7β-OH-DHEA, 7-oxo-DHEA, DHEA) and secondary (balance, cognition and patient-reported outcomes) outcomes were examined three times (pre, post, and washout assessments). Results: In both groups, there is a decreasing trend of 7-oxo-DHEA concentration in post-assessment and 7β-OH-DHEA in washout versus pre-assessment. A higher impact on neuroactive steroids is visible after Vojta’s reflex locomotion. As for clinical outcomes, the Paced Auditory Serial Addition Test and Multiple Sclerosis Impact Scale significantly improved between post-assessment and washout assessment. The improvement was similar for both treatments. Conclusions: Neuroproprioceptive facilitation and inhibition improved the clinical outcomes and led to non-significant changes in neuroactive steroids. Trial registration (NCT04379193).

Verified
Journal Article
Open access
PDF file
Martin HillMartin Hill
Martin Hill
RKRadmila Kancheva
Radmila Kancheva
MVMarta Velíková
Marta Velíková
LKLudmila Kančeva
Ludmila Kančeva
JVJosef Vcelak
Josef Vcelak
EHEva Kubala Havrdová
Eva Kubala Havrdová
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system. The manifestation of MS is related to steroid changes during the menstrual cycle and pregnancy. As data focusing on the effect of anti-MS drug treatment on steroidome are scarce, we evaluated steroidomic changes (79 steroids) in 61 female MS patients of reproductive age 39 (29, 47) years (median with quartiles) after treatment with anti-MS drugs on the GC-MS/MS platform and immunoassays (cortisol and estradiol). The changes were assessed using steroid levels and steroid molar ratios (SMRs) that may reflect the activities of steroidogenic enzymes (SMRs). A repeated measures ANOVA, followed by multiple comparisons and OPLS models, were used for statistical analyses. The anti-MS treatment decreased steroid levels in the follicular phase. Anti-CD20 monoclonal antibodies (mAb), such as ofatumumab and ocrelizumab; inhibitors of the sphingosine-1-phosphate receptor (S1PRI); and IFNβ-1a decreased circulating 17-hydroxy-pregnanes and shifted the CYP17A1 functioning from the hydroxylase- toward the lyase step. Decreased conjugated/unconjugated steroid ratios were found after treatment with anti-MS drugs, especially for glatiramer acetate and anti-CD20 mAb. In the luteal phase, IFN-β1a treatment increased steroidogenesis; both IFN-β1a and ocrelizumab increased AKR1D1, and S1PRI increased SRD5A functioning. Anti-CD20 mAb reduced the functioning of enzymes catalyzing the synthesis of immunomodulatory 7α/β and 16α-hydroxy-androgens, which may affect the severity of MS. The above findings may be important concerning the alterations in bioactive steroids, such as cortisol; active androgens and estrogens; and neuroactive, neuroprotective, and immunomodulatory steroids in terms of optimization of anti-MS treatment.

29 October 2026 in The Prostate
Verified
Journal Article
Open access
JHJiri Heracek
Jiri Heracek
LGLukas Gadus
Lukas Gadus
MHMichal Horenitzky
Michal Horenitzky
MNMarie Novakova
Marie Novakova
TŠTereza Škodová
Tereza Škodová
Jana VitkuJana Vitku
Jana Vitku
Background: Circulating steroid trajectories after robot‐assisted radical prostatectomy are poorly characterized from the day‐of‐surgery baseline, and relevant biology extends beyond testosterone and dihydrotestosterone to adrenal‐derived 11‐oxygenated androgens and steroid conjugate turnover. This study aimed to characterize 3‐ and 6‐month plasma steroid differences from a day‐of‐surgery baseline and evaluate baseline steroid biomarkers for adverse pathology, upgrading, and early detectable prostate‐specific antigen (PSA). Methods: This prospective, single‐center cohort included 173 men undergoing robot‐assisted radical prostatectomy. Fasting plasma was sampled before premedication on the morning of surgery and at 3 and 6 months. A 34‐analyte steroid panel, including conjugated analytes, was quantified using liquid chromatography–tandem mass spectrometry. Longitudinal differences were analyzed using mixed‐effects models. Baseline screening used logistic regression with false discovery rate correction and adjusted models for retained signals. Results: For most analytes, 168–170 baseline samples and 131/108 samples at 3/6 months were available. Relative to baseline, 11‐ketotestosterone increased at 3 and 6 months (fold changes 1.36 [95% CI 1.24–1.49] and 1.25 [1.13–1.38]), corticosterone decreased (0.61 [0.52–0.70] and 0.59 [0.51–0.69]), cortisol decreased (0.91 [0.84–1.00] and 0.86 [0.78–0.94]), and conjugated corticosterone/corticosterone increased (1.96 [1.57–2.45] and 2.41 [1.90–3.06]), all p < 0.04. At 6 months, neither testosterone (fold change 0.88; 95% CI 0.75–1.03) nor dihydrotestosterone (0.90; 0.79–1.04) differed significantly from the day‐of‐surgery baseline. The conjugated/unconjugated estrone ratio (E1C/E1) was the only retained baseline adverse‐pathology signal, with inverse adjusted associations for pT3a/b disease (OR 0.61; 95% CI 0.41–0.90; p = 0.013) and composite adverse pathology (OR 0.53; 95% CI 0.36–0.78; p = 0.001). No biomarker remained significant for upgrading or detectable PSA. Conclusions: Relative to the day‐of‐surgery baseline, longitudinal differences involve corticosteroid‐related and 11‐oxygenated analytes, but their mechanisms remain unresolved. These data define postoperative steroid trajectories from a day‐of‐surgery baseline without establishing prostatectomy‐specific endocrine effects. Baseline E1C/E1 warrants external validation as a hypothesis‐generating marker of adverse pathology.

15 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Martin HillMartin Hill
Martin Hill
RKRadmila Kancheva
Radmila Kancheva
MVMarta Velíková
Marta Velíková
LKLudmila Kančeva
Ludmila Kančeva
JVJosef Vcelak
Josef Vcelak
EHEva Kubala Havrdová
Eva Kubala Havrdová
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system. The manifestation of MS is related to steroid changes during the menstrual cycle and pregnancy. As data focusing on the effect of anti-MS drug treatment on steroidome are scarce, we evaluated steroidomic changes (79 steroids) in 60 female MS patients of reproductive age 39 (29, 47) years (median with quartiles) after treatment with anti-MS drugs on the GC-MS/MS platform and immunoassays (cortisol and estradiol). The changes were assessed using steroid levels and steroid molar ratios that may reflect activities of steroidogenic enzymes (SMRs). A repeated measures ANOVA followed by multiple comparisons and OPLS models were used for statistical analyses. The anti-MS treatment decreased steroid levels in follicular phase. Anti-CD20 monoclonal antibodies (mAb) such as ofatumumab and ocrelizumab, inhibitors of the sphingosine-1-phosphate receptor (S1PRI), and IFNβ-1a decreased circulating 17-hydroxy-pregnanes and shifted the CYP17A1 functioning from the hydroxylase- toward the lyase step. Decreased conjugated/unconjugated steroid ratios were found after treatment with anti-MS drugs, especially for glatiramer acetate and anti-CD20 mAb. In the luteal phase, IFN-β1a treatment increased steroidogenesis, and both IFN-β1a and ocrelizumab increased AKR1D1 and S1PRI increased SRD5A functioning. Anti-CD20 mAb reduced the functioning of enzymes catalyzing the synthesis of immunomodulatory 7α/β and 16α-hydroxy-androgens, which may affect the severity of MS. The above findings may be important concerning the alterations in bioactive steroids such as cortisol, active androgens and estrogens, neuroactive, neuroprotective and immunomodulatory steroids in terms of optimization of anti-MS treatment.

13 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RKRadmila Kancheva
Radmila Kancheva
EHEva Kubala Havrdová
Eva Kubala Havrdová
MVMarta Velíková
Marta Velíková
LKLudmila Kancheva
Ludmila Kancheva
JVJosef Vcelak
Josef Vcelak
Martin HillMartin Hill
Martin Hill
Multiple sclerosis (MS) is a long-term disease, causing inflammation and damage to the nervous system. This study evaluated steroidomic alterations related to MS in 57 female MS patients during the follicular phase and 17 during the luteal phase, as well as in age- and phase-matched controls. The data showed 1) Unconjugated and conjugated steroids were strongly linked between the blood and CSF. 2) MS patients have lower levels of unconjugated steroids compared to controls. However, unchanged levels of conjugated steroids indicate increased activity of steroid sulfotransferase. 3) MS patients have reduced functioning of steroid 11β-hydroxylase (CYP11B1). Problems with cortisol biosynthesis, linked to weakened functioning of both CYP11B1 and 17α-hydroxylase/17,20-lyase, are connected to more severe cases of MS. 4) Reduced levels of 5α/β-steroids and protective GABAergic 3α-hydroxy-5α/β-steroids in MS patients might be linked to the pathophysiology of MS. 5) Higher AKR1C3 function in MS could cause inflammation, as this enzyme catalyzes the synthesis of both steroids and prostaglandins. 6) Lower pregnenolone levels in MS patients might weaken neuroprotection, while higher pregnenolone sulfate levels could support cognitive function. 7) Lower levels of protective pregnenolone, DHEA, and androstenediol were associated with worse MS, suggesting these steroids may help shield against the disease.